PRICKLE4 and central nervous system cancer: Collectively, these findings identified the Prickle4‐mediated microenvironmental remodeling as the key resistance mechanism to PARPi, and support the therapeutic promise of multimodal therapy combining PARPi with anti‐angiogenic agents for glioma treatment.